Research and Clinical Trials
The following are Industry Sponsored Clinical Research (ISR) currently conducted at the various centres. For further information, please contact the Principal Investigator.
No content at this moment
Early Stage Breast Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| ER+, HER2- Early Stage Breast Cancer | A Phase III, Randomized, open labelled, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician’s choice of adjuvant endocrine monotheraphy in patients with estrogen receptor-positive, HER-2 negative early breast cancer (GO42784 – lidERA Breast Cancer) | University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my |
SC: Aziera 03-79492120 (Research Room) | CLICK HERE |
| Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad drazura@beaconhospital.com.my
03 – 7787 2830 |
General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email) | |||
| Pantai Hospital Sungai Petani | Dr Shazril Imran Shaukat | General line : 04 4428 888 (Ext. 8987) | |||
| National Cancer Institute (IKN) | Dr Winnie Ng Nyek Ping drwinnie@nci.gov.my | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) / 03- 8892 5622 (Fax) | |||
| Hospital Pulau Pinang | Dr Fong Chin Heng fongchinheng@gmail.com | General line: 04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 – Dr. Yoon Chee Kin, Ketua Jabatan dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar, Admin Manager zarinacu@gmail.com (Email) |
Advanced Breast Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Subtype: HER2-Negative | |||||
| HER2-negative with APOBEC3B Protein | Phase II, Single Arm, Open Label, Simon Two-Stage Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients: Evaluation of Impact of Germline Variants in APOBEC3B (AUROR) | University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my |
SC: Yok Yong 03-79492120 (Research Room) |
CLICK HERE |
| Subtype: HR-Positive & HER2-negative | |||||
| Phase II, Line of treatment: 1st & 2nd Line, Failed endocrine therapy, PIK3CA mutation | A phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (EPIK-B4) | University of Malaya Medical Centre (UMMC) | DR ADLINDA ALIP adlinda@ummc.edu.my |
SC: Kimee Ku 03-79492120 (Research Room) | CLICK HERE |
| National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK suhanayusak@gmail.com | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) / 03- 8892 5622 (Fax) |
|||
| Kuala Lumpur Hospital (HKL) | DR IBTISAM MUHAMAD NOR maryamsofiyyah@yahoo.com.my | General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook) |
|||
| Pulau Pinang Hospital | DR CHOONG SWEE HSIA shchoong83@gmail.com | General line: 04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 Dr. Yoon Chee Kin, Ketua Jabatan dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar, Admin Manager zarinacu@gmail.com (Email) |
|||
| Phase III, Line of treatment: 1nd Line, Received at least 24 months of AI treatment as part of their adjuvant therapy and at least 12 months have elapsed since the patient’s last dose of adjuvant AI therapy without disease progression on treatment | A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4) | Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI john.low@pantaidr.my | General Line: 03 – 2296 0888 CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322 |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my |
SC: Wei Ying 03-79492120 (Research Room) |
|||
| Kuala Lumpur Hospital (HKL) | Dr Vaishnavi Jeyasingam vaishnavijeyasingam@yahoo.com | General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook) |
|||
| Sarawak General Hospital | DR Syadwa Binti Abdul Shukor assyadwa@gmail.com | General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
|||
| Pulau Pinang Hospital | DR CHOONG SWEE HSIA shchoong83@gmail.com | General line: 04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 Dr. Yoon Chee Kin, Ketua Jabatan dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar, Admin Manager zarinacu@gmail.com (Email) |
|||
| National Cancer Institute (IKN) | DR WONG YOKE FUI florencefui@yahoo.com |
General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) / 03- 8892 5622 (Fax) |
|||
| HR+, HER2- Locally Recurrent Inoperable Metastic Breast Cancer Failed Endocrine Therapy for Chemotherapy-Candidate | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49) | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF drmasturamy@gmail.com 03 – 2296 0764 | General Line: 03 – 2296 0888 CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322 |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | DR NUR FADHLINA ABDUL SATAR fadhlinas@ummc.edu.my | SC: Kimee Ku 03-79492120 (Research Room) | |||
| Kuala Lumpur Hospital (HKL) | Dr Eznal Izwadi Mohd Mahidin eznal.mahidin@gmail.com | General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook) |
|||
| Hospital Pulau Pinang | Dr Tan Ai Lian ailian.tan@gmail.com | General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook) | |||
| Sarawak General Hospital | DR VOON PEI JYE voonpj@yahoo.com | ‘General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com, crcsghkuching@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) | |||
| Phase III, Line of treatment: 2nd &3rd Line , Failed endocrine therapy | A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor- Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPITELLO-292) | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF drmasturamy@gmail.com 03 – 2296 0764 |
General Line: 03 – 2296 0888 CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322 |
CLICK HERE |
| National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK suhanayusak@gmail.com |
General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) / 03- 8892 5622 (Fax) |
|||
| Subtype: HR-Negative & HER2-negative (Triple Negative) | |||||
| Homologous recombinat Deficiency Metastatic Breast Cancer in Asian | Phase II Study to assess the efficacy of Talazoparib in asian mEtastatic breast caNcer patients with a hOmologous Recombinant deficiency (HRD) signature (TENOR) | University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | SC: Wei Ying 03-79492120 (Research Room) | CLICK HERE |
| Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF drmasturamy@gmail.com 03 – 2296 0764 | General Line: 03 – 2296 0888 CRC: 03 – 2781 0888 Ext 4519/4520/4522 | |||
| Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN chunsen1@hotmail.com | General line: 07 – 356 5000 CRC: 07 – 356 5000 ext: 2408 / Dr Munirah Admin Manager drmunirah@hsi.gov.my (Email) |
|||
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Adult women with Platinum Resisitant or Refractory High-Grade Serous Ovarian Cancer with No BRCA Germline Mutated | A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer (EPIK-O) | University of Malaya Medical Centre (UMMC) | DR ROZITA ABDUL MALIK rozita@ummc.edu.my | SC: Yok Yong 03-79492120 (Research Room) |
CLICK HERE |
| Kuala Lumpur Hospital (HKL) | DR NOOR ZAFIFAH BINTI ZAKARIA zazajaka@gmail.com |
General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook) |
|||
| Hospital Wanita dan Kanak-Kanak Sabah | DR SOON RUEY rueysoon@yahoo.com | General line: 08 – 8522 600 Ext. 2272 |
Head & Neck Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| HRAS Mutation | The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN) (KO-TIP-007) | University of Malaya Medical Centre (UMMC) | DR NUR FADHLINA ABDUL SATAR fadhlinas@ummc.edu.my |
SC: Kimee Ku 03-79492120 (Research Room) |
CLICK HERE |
| National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK suhanayusak@gmail.com | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) / 03- 8892 5622 (Fax) |
|||
| Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC) | Sarawak General Hospital | DR VOON PEI JYE voonpj@yahoo.com | General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
CLICK HERE |
| Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN chunsen1@hotmail.com | General line: 07 – 356 5000 CRC: 07 – 356 5000 ext: 2408 / Dr Munirah, Admin Manager drmunirah@hsi.gov.my (Email) |
|||
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | SC: Kimee 03-79492120 (Research Room) | |||
| National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK suhanayusak@gmail.com | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) / 03- 8892 5622 (Fax) |
|||
| Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER) | University of Malaya Medical Centre (UMMC) | DR WAN ZAMANIAH wzamaniah@ummc.edu.my | SC: Suga 03-79492120 (Research Room) | CLICK HERE |
Naasopharyngeal Carcinoma
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Recurrent / Metastatic NPC | An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma ( VT3996-301) | Sarawak General Hospital | DR VOON PEI JYE voonpj@yahoo.com |
General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com, crcsghkuching@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
CLICK HERE |
Thyroid Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Locally Advaanced or Metastatic BRAFV600E Mutation-Positive, Differentiated Thyroid Carcinoma Who Are Refractory to Radioactive Iodine and Have Progressed following Prior VEGFR Targeted Therapy | A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib plus Trametinib in Previously Treated Patients with Locally Advanced or Metastatic, Radio-Active Iodine Refractory BRAFV600E Mutation-Positive Differentiated Thyroid Cancer (CDRB436J12301) | Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI john.low@pantaidr.my | General Line: 03 – 2296 0888 CRC: 03 – 2781 0888 Ext 4519/4520/4522 |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | DR WAN ZAMANIAH wzamaniah@ummc.edu.my | SC: Yok Yong 03-79492120 (Research Room) |
|||
| Kuala Lumpur Hospital | DR IBTISAM MUHAMAD NOR maryamsofiyyah@yahoo.com.my | General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook) |
|||
| Hospital Pulau Pinang | DR CHOONG SWEE HSIA shchoong83@gmail.com | General line: 04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 – Dr. Yoon Chee Kin Ketua Jabatan dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar Admin Manager zarinacu@gmail.com (Email) |
|||
| Sarawak General Hospital | DR HADI BIN AB.JALIL hadiabjalil@gmail.com | General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Locally Advanced or metastatic Hepatocellular Carcinoma (HCC) Who Have Progressed On Prior Systemic Treatment with Atezolizumab plus Bevacizumab Combination. | A phase III, open-label, randomized study of atezolizumab with lenvatinib or sorafenib versus lenvatinib or sorafenib alone in HCC previously treated with atezolizumab and bevacizumab (IMbrave251) | University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | SC: Alice 03-79492120 (Research Room) |
CLICK HERE |
| Beacon Hospital | Dr Tho Lye Mun tholm@beaconhospital.com.my | General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email) |
|||
| National Cancer Institute (IKN) | DR WONG YOKE FUI florencefui@yahoo.com | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) / 03- 8892 5622 (Fax) |
|||
| Participant with Complete Radiological Response after Surgical Resection and Local Ablation | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) | National Cancer Institute (IKN) | DR WONG YOKE FUI, Florence dryfwong@nci.gov.my | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 4168 (Tel) / 03- 8892 5622 (Fax) / Siti Fatimah Zahra Mohd Anuar Pengurus Pentadbiran fatimahzahra@crc.moh.gov.my (Email) |
CLICK HERE |
| Sarawak General Hospital | DR LIM YUEH NI ynlim1001@yahoo.com | General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
|||
| Adventist Penang | Dr. Ang Soo Fan angsoofan@pah.com.my 04-222 7490/7491/7339 |
General line: 04-2227200 CRC: 04 222 7652 / 7653 (Tel) / researchcentre@pah.com.my (Email) |
|||
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | SC: Alice 03-79492120 (Research Room) |
|||
| Recurrent/Metastatic Hepatocellular Carcinoma | An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC) | Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN chunsen1@hotmail.com | General line: 07 – 356 5000 CRC: 07 – 356 5000 ext: 2408 / Dr Munirah, Admin Manager drmunirah@hsi.gov.my (Email) |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | SC: Kimee 03-79492120 (Research Room) |
|||
| National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK suhanayusak@gmail.com | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) 03- 8892 5622 (Fax) |
|||
| Sarawak General Hospital | DR VOON PEI JYE voonpj@yahoo.com | General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
|||
| Locoregional Hepatocellular Carcinoma | A Phase III, Randomized, Open -Label, Sponsor-Blinded, MulticentreStudy of Durvalumab in Combination With Tremelimumab with/without Levatinib Given Concurrently with TACE Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) | Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI john.low@pantaidr.my |
General Line: 03 – 2296 0888 CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322 |
|
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my |
SC: Wei Ying 03-79492120 (Research Room) | |||
| Hospital Al Sultan Abdullah (UiTM Hospital) | Dr Ahmad Ramzi Yusoff rami992@uitm.edu.my |
CRC: 03-6126 7461 (Tel) / 03-6126 7479 (Fax) / centremedic@uitm.edu.my (email) / https://medicine.uitm.edu.my/centre (website) SC: Sazreza Shahdan, Irda Yasmoon Awang |
|||
| National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK suhanayusak@gmail.com |
General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) / 03- 8892 5622 (Fax) |
Colorectal Cancer – Early Stage Colorectal Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Dukes C and High Risk Dukes B Colorectal Cancers | Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers (ASCOLT) | University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | SC: Kimee Ku 03-79492120 (Research Room) SC: Alice 03-79492120 (Research Room) |
CLICK HERE |
Colorectal Cancer – Advanced Colorectal Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (ORIGAMI1) | Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) clinicalresearch@beaconhospital.com.my (Email) | CLICK HERE | |
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | 03-79492120 (Research Room) | |||
| Sarawak General Hospital | DR VOON PEI JYE voonpj@yahoo.com | General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) | |||
| Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy | A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (Krystal-10) | Beacon Hospital Sdn Bhd | Dato’ Dr Mohamed Ibrahim A Wahid dribrahim@beaconhospital.com.my 03 – 7620 7979 03 – 7787 2992 (Ext: 2868) |
General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) clinicalresearch@beaconhospital.com.my (Email) |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my |
SC Wei Ying: 03-79492120 (Research Room) | |||
| Kuala Lumpur Hospital (HKL) | DR IBTISAM MUHAMAD NOR maryamsofiyyah@yahoo.com.my |
General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook) |
|||
| Sultan Ismail Hospital, Johor Bahru | Dr. Rangasamy Ramachandran | General line: 07 – 356 5000 CRC: 07 – 356 5000 ext: 2408 / Dr Munirah, Admin Manager drmunirah@hsi.gov.my (Email) |
|||
| National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK suhanayusak@gmail.com |
General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) 03- 8892 5622 (Fax) |
Early Stage Lung Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Phase III, Stage 1A2 and 1A3,Complete Resection, EGFR Mutation, Line of Therapy: Adjuvant | A Phase III, Double blind, Randomised, Placebo Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2 IA3 Non small Cell Lung Cancer, following Complete Tumour Resection (ADAURA2) | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF drmasturamy@gmail.com 03 – 2296 0764 |
General Line: 03 – 2296 0888 CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322 |
CLICK HERE |
| Beacon Hospital Sdn Bhd | DR THO LYE MUN drtho.oncology@gmail.com | General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email) |
|||
| Hospital Pulau Pinang | Dr Tan Ai Lian ailian.tan@gmail.com | General line: ‘ 04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 – Dr. Yoon Chee Kin, Ketua Jabatan dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar, Admin Manager zarinacu@gmail.com (Email) |
|||
| Sarawak General Hospital | DR VOON PEI JYE voonpj@yahoo.com | General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
|||
| Phase III, Stage III, Received concurent chemradiation with no progression, PD-L1 positive | A Phase 3, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy (PACIFIC-8) | Hospital Sultan Ismail | DR LIM CHUN SEN chunsen1@hotmail.com |
General line: 07 – 356 5000 CRC: 07 – 356 5000 ext: 2408 Dr Munirah Admin Manager drmunirah@hsi.gov.my (Email) |
CLICK HERE |
| Sarawak General Hospital | DR VOON PEI JYE voonpj@yahoo.com |
General line: 082 – 276666 CRC: 082-276820 (Tel) 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
|||
| Beacon Hospital Sdn Bhd | Dato’ Dr Mohamed Ibrahim A Wahid | General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email) |
|||
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my |
SC: Kimee 03-79492120 (Research Room) | |||
| Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI john.low@pantaidr.my |
General Line: 03 – 2296 0888 CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322 |
|||
| Phase III, Stage IIIA; IIIB; IIIC, No prior treatment (chemotheraphy, radiotherapy & immunotherapy) for Stage III | Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC (MK-7684A-006/KEYVIBE-006) | University of Malaya Medical Centre (UMMC) | DR ADLINDA ALIP adlinda@ummc.edu.my | SC Kimee : 03-79492120 (Research Room) |
Advanced Lung Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Phase Ib, Line of therapy: 1st line, Non-squamous with HER2 overexpression | A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination With Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03) | Sarawak General Hospital | DR VOON PEI JYE voonpj@yahoo.com | General line: 082 – 276666 CRC: 082-276820 (Tel) 082-276823 (Fax) Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480 (Facebook) |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | SC: Alice 03-79492120 (Research Room) |
|||
| National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK suhanayusak@gmail.com | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) 03- 8892 5622 (Fax) |
|||
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN hwoeifen@yahoo.com | General line: 04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 Dr. Yoon Chee Kin, Ketua Jabatan dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar, Admin Manager zarinacu@gmail.com (Email) |
|||
| Phase II, Line of therapy: 1st line, EGFR mutation | A Single-arm, Open-label, Phase 2 Study of Dacomitinib With or Without Dose Titration for the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Subjects With an Epidermal Growth Factor Receptor (EGFR) Activation Mutation (ATORG003) | Sarawak General Hospital | DR LIM YUEH NI ynlim1001@yahoo.com | General line: 082 – 276666 CRC: 082-276820 (Tel) 082-276823 (Fax) Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480 (Facebook) |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | SC: Yok Yong 03-79492120 (Research Room) |
|||
| Beacon Hospital Sdn Bhd | DR THO LYE MUN drtho.oncology@gmail.com | General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) clinicalresearch@beaconhospital.com.my (Email) |
|||
| Phase II, Line of therapy: 1st Line & 2nd line, EGFR mutation | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer (PALOMA-2) | University of Malaya Medical Centre (UMMC) | CLICK HERE | ||
| Beacon Hospital Sdn Bhd | DR THO LYE MUN drtho.oncology@gmail.com | General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) clinicalresearch@beaconhospital.com.my (Email) |
|||
| Sarawak General Hospital | DR VOON PEI JYE voonpj@yahoo.com | General line: 082 – 276666 CRC: 082-276820 (Tel) 082-276823 (Fax) Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
|||
| Tengku Ampuan Afzan Hospital, Kuantan | PROF DR HOW SOON HIN how_sh@yahoo.com | CRC: 09-5572923 Ext: 2922/2928 (Tel) 09-5139378 (Fax) crchtaa@gmail.com (Email) |
|||
| Phase II, Line of therapy: 1st Line, squamous or nonsquamous, KRAS G12C mutation and PD-L1 TPS ≥ 1% | A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-17) | National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK suhanayusak@gmail.com | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) 03- 8892 5622 (Fax) |
CLICK HERE |
| Phase III, Line of therapy: 1st line, Squamous & Nonsquamous | A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304) | Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) clinicalresearch@beaconhospital.com.my (Email) |
CLICK HERE |
| Tengku Ampuan Afzan Hospital, Kuantan | DR AISHAH BINTI IBRAHIM aishibr@gmail.com | CRC: 09-5572923 Ext: 2922/2928 (Tel) /09-5139378 (Fax) crchtaa@gmail.com (Email) |
|||
| Sarawak General Hospital | DR AIDEN HENG FOOK YEW hengfy.onco@gmail.com |
General line: 082 – 276666 CRC: 082-276820 (Tel) 082-276823 (Fax) Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480 (Facebook) |
|||
| National Cancer Institute (IKN) | DR WONG YOKE FUI florencefui@yahoo.com +603 8892 5555 ext 4281 |
General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) 03- 8892 5622 (Fax) |
|||
| Phase III, Line of therapy: 1st line, EGFR mutation | Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) | Tengku Ampuan Afzan Hospital, Kuantan | PROF DR HOW SOON HIN how_sh@yahoo.com | CRC: 09-5572923 Ext: 2922/2928 (Tel) 09-5139378 (Fax) crchtaa@gmail.com (Email) |
CLICK HERE |
| Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN drmuthuk@gmail.com | General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) crc.hkl@moh.gov.my (email) Crc Hkl Clinical Research Centre HKL (Facebook) SC: Amirah 017-233 6295 |
|||
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | General line: 04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 Dr. Yoon Chee Kin, Ketua Jabatan dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar, Admin Manager zarinacu@gmail.com (Email) |
|||
| Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) clinicalresearch@beaconhospital.com.my (Email) |
|||
| University of Malaya Medical Centre (UMMC) | DR ADLINDA ALIP adlinda@ummc.edu.my | SC: Yok Yong 017 268 0664 |
|||
| Phase III, Line of therapy: 1st line, PD-L1 positive (Central confirmation) | A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer MK 7684A-003 | National Cancer Institute (IKN) | Dr Winnie Ng Nyek Ping +603 8892 5555 ext 4281 |
General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) 03- 8892 5622 (Fax) |
|
| Tengku Ampuan Afzan Hospital, Kuantan | DR HOW SOON HIN how_sh@yahoo.com | CRC: 09-5572923 Ext: 2922/2928(Tel) 09-5139378 (Fax) crchtaa@gmail.com (Email) |
|||
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | CIC (Research Room) : 03-79492120 (Tel) |
|||
| Pulau Pinang Hospital | DR FONG CHIN HENG fongchinheng@gmail.com | General line: 04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 Dr. Yoon Chee Kin, Ketua Jabatan dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar, Admin Manager zarinacu@gmail.com (Email) |
|||
| Glenagles Hospital Penang | |||||
| Phase III, Line of Therapy: 2nd line, EGFR mutation, Prgreesed afrer one line of TKI Inhibitor (1st or @nd generation) | A phase III randomized, controlled, open-label, multicenter, global study of capmatinib in combination with osimertinib versus platinum – pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior 1st / 2nd generation EGFR‑TKI or osimertinib therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) | Sunway Medical Centre | Dr. Jennifer Leong | CRC: 03-8601 1079 (Tel) 03-8601 1069 (Fax) sunmed-crc@sunway.cm.my edwinbt@sunway.com.my (email) |
CLICK HERE |
| Phase III, Line of therapy: 2nd & 3rd line, Progreesion after osimenitib at most recent therapy. | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2) | Mount Miriam Cancer Hospital Penang | Dr Ang Tick Suan angts@mountmiriam.com 04-8923907 |
General line: 04 – 892 3999 | CLICK HERE |
| University of Malaya Medical Centre (UMMC) | DR TAN JIUNN LIANG | 03-79492120 (Research Room) | |||
| Beacon Hospital Sdn Bhd | Dato’ Dr Mohamed Ibrahim A Wahid | General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) clinicalresearch@beaconhospital.com.my (Email) |
|||
| Subang Jaya Medical Centre | |||||
| Tengku Ampuan Afzan Hospital, Kuantan | PROF DR HOW SOON HIN how_sh@yahoo.com |
CRC: 09-5572923 Ext: 2922/2928 (Tel) 09-5139378 (Fax) crchtaa@gmail.com (Email) |
|||
| Phase III, Lin eo ftherpy: 3rd line, Has received one line of platinum-based cchemothherapy and one line of immune checkpoint habitor, KRAS G12C (Central confirmation) | A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02) | University of Malaya Medical Centre (UMMC) | DR PANG YONG KEK | 03-79492120 (Research Room) | CLICK HERE |
| Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF drmasturamy@gmail.com 03 – 2296 0764 | General Line: 03 – 2296 0888
CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322 |
|||
| Sunway Medical Centre | Dr Kow Ken Siong | edwinbt@sunway.com.my (Email)
+603 – 74919191/ 603-8601 1081 |
|||
| Phase III, Line of Therapy : 3rd line, Progressed after osimernitib and platinum based chemotherapy | A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Administered Via Manual Injection Compared With Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy (PALOMA-3) | Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI john.low@pantaidr.my | General Line: 03 – 2296 0888
CRC: 03 – 2781 0888 Ext 4519/4520/4522 |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | |||||
| Prince Court Medical Centre (PCMC) | Dr Muhammad Azrif Ahmad Annuar | General line : 03 – 2160 0000 | |||
| Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | General line: 03 7620 7979 / 03 7787 2992CRC: 03 -7787 2854 (Tel) clinicalresearch@beaconhospital.com.my (Email) |
|||
| Sunway Medical Centre | Dr Kow Ken Siong | edwinbt@sunway.com.my (Email)
+603 – 74919191/ 603-8601 1081 |
|||
| Sarawak General Hospital | DR VOON PEI JYE voonpj@yahoo.com | General line: 082 – 276666 CRC: 082-276820 (Tel) 082-276823 (Fax) Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480 (Facebook) |
No content at this moment
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA) (HERIZON-GEA-01) | University of Malaya Medical Centre (UMMC) | DR WAN ZAMANIAH wzamaniah@ummc.edu.my | SC: Yok Yong 03-79492120 (Research Room) |
CLICK HERE | |
| Pantai Hospital Kuala Lumpur | DR LAM KAI SENG drkslam@gmail.com | General Line: 03 – 2296 0888 CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322 |
|||
| Hospital Pulau Pinang | DR FONG CHIN HENG fongchinheng@gmail.com | General line: ’04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 – Dr. Yoon Chee Kin, Ketua Jabatan dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar Admin Manager zarinacu@gmail.com (Email) |
|||
| IKN | DR WONG YOKE FUI, Florence florencefui@yahoo.com | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) 03- 8892 5622 (Fax) |
Bladder Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Cisplatin-eligible participants with muscle-invasive bladder cancer | A Phase 3, Randomized, Open-Label Study to Evaluavate Perioperative Enfortumab Vedotin plus Pembrolizumab (MK-3475) versus Neodjuvant gemcitabine and cisplatin in cisplatin-eligible participants with muscle-invasive bladder cancer (KEYNOTE-B15/EV-304) | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD marniza@ummc.edu.my |
Cryst Sari 03-79492120 (Research Room) |
CLICK HERE |
| Cisplatin-ineligible participants with muscle-invasive bladder cancer | A Randomized phase 3 study evaluating cystectomy with perioperative pembrolizumab and cystectomy with perioperative enfortumab vedotin and pembrolizumab versus cystectomy alone in cisplatin-ineligible participants with muscle-invasive bladder cancer (KEYNOTE 905) | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD marniza@ummc.edu.my |
SC: Suga 03-79492120 (Research Room) | CLICK HERE |
| Muscle-invasive bladder cancer | A phase 3, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC) (KEYNOTE 992) | Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN drmuthuk@gmail.com 03-2615 5830 |
General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) SC: Amirah 017-233 6295 |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD marniza@ummc.edu.my |
SC: Cryst Sari 03-79492120 (Research Room) |
|||
| Sunway Medical Centre | Dr Nik Muhd Aslan Dr’s Clinic: 03-74919191 (Ext: 28025) | CRC: 03-8601 1079 (Tel) / 03-8601 1069 (Fax) |
|||
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN hwoeifen@yahoo.com |
General line: 04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 |
Prostate Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Metastatic Castration-Sensitive Prostate Cancer, Deleterious Germline or Somatic Hmologous Recombinatin Repair Gene-Mutated | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration- Sensitive Prostate Cancer (mCSPC) (AMPLITUDE) | Kuala Lumpur Hospital (HKL) | DR PRATHEPAMALAR A/P YEHGAMBARAM prathepa82@gmail.com | General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook) SC: Amirah 017-233 6295 |
CLICK HERE |
| Sarawak General Hospital | DR HADI BIN AB.JALIL hadiabjalil@gmail.com | General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
|||
| National Cancer Institute (IKN) | DR WONG YOKE FUI florencefui@yahoo.com | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) / 03- 8892 5622 (Fax) |
|||
| Pulau Pinang Hospital | DR FONG CHIN HENG fongchinheng@gmail.com | General line: ’04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 – Dr. Yoon Chee Kin, Ketua Jabatan dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar Admin Manager zarinacu@gmail.com (Email) |
|||
| University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD marniza@ummc.edu.my | SC: Cryst Sari 03-79492120 (Research Room) |
|||
| Metastic Prostate Cancer | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer (MAGNITUDE) | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD marniza@ummc.edu.my |
SC: Cryst Sari 03-79492120 (Research Room) |
CLICK HERE |
Renal Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (MK6482-012) |
University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD marniza@ummc.edu.my | SC: Cryst Sari 03-79492120 (Research Room) |
CLICK HERE |
| Kuala Lumpur Hospital (HKL) | DR IBTISAM MUHAMAD NOR maryamsofiyyah@yahoo.com.my | General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook) |
|||
| National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK suhanayusak@gmail.com | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) / 03- 8892 5622 (Fax) |
|||
| Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN chunsen1@hotmail.com | CRC: 03-8601 1079 (Tel) / 03-8601 1069 (Fax) / sunmed-crc@sunway.cm.my edwinbt@sunway.com.my (email) |
|||
| ccRCC Post Nephrectomy | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022) | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD marniza@ummc.edu.my | SC: Cryst Sari: 03-79492120 (Research Room) | CLICK HERE |
| Sarawak General Hospital | DR VOON PEI JYE voonpj@yahoo.com | General line: 082 – 276666 CRC: 082-276820 (Tel) 082-276823 (Fax) Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
|||
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN hwoeifen@yahoo.com | General line: 04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 Dr. Yoon Chee Kin, Ketua Jabatan dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar, Admin Manager zarinacu@gmail.com (Email) |
Breast Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Breast Cancer | Studies of Epigenetic Changes in Blood Samples in Breast Cancer Patients (EPIGENECTIC) | Kuala Lumpur Hospital (HKL) | Dr Ros Suzanna Ahmad Bustamam rossuzanna@gmail.com 03-26155810 |
General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook) |
|
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my |
SC: Alice 03-79492120 (Research Room) |
|||
| Use of an online Asian Genetic Risk Calculator to improve the uptake of genetic counselling and genetic testing among breast cancer patients (The ARiCa Study) | Pantai Hospital Kuala Lumpur | Dr Azlina Firzah Abdul Aziz | General Line: 03 – 2296 0888 Clinic: 03-2296 0837 |
||
| Subang Jaya Medical Cnetre | Professor Emeritus Dato’ Dr Yip Cheng Har | General Line: 03-5639 1212 | |||
| HER2+ Advanced Breast Cancer in Asian Women | Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer (EXEMASTANE) | University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | SC: Yok Yong 03-79492120 (Research Room) |
CLICK HERE |
| Advanced Breast Cancer | Living well with advanced breast cancer (HAPPINESS Registry) | University of Malaya Medical Centre (UMMC) | |||
| Pantai Hospital Kuala Lumpur |
Prostate Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Metastatic Prostate Cancer | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (Observational) (PREVALENCE) | Sarawak General Hospital | DR HADI BIN AB.JALIL hadiabjalil@gmail.com | ‘General line: 082 – 276666
CRC: 082-276820 (Tel) |
CLICK HERE |
| Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN drmuthuk@gmail.com | General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel) |
|||
| University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD marniza@ummc.edu.my | SC: Cryst Sari 03-79492120 (Research Room) |
|||
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN hwoeifen@yahoo.com | General line: 04-2225 333
CRC: 042225 767 / 2225 762 / dryoonck@moh.gov.my (email) |
Lung Cancer
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Advanced Non Small Cell Lung Cancer with EGFR mutation on Dacomitinib as First Line Treatment for Asian Patients (Observational) | Real-World Utilization and Outcomes with Dacomitinib First-Line Treatment for EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer among Asian Patients – A Multi-Center Chart Review (ARIA) | University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | SC: Wei Ying 03-79492120 (Research Room) |
CLICK HERE |
| Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI john.low@pantaidr.my | General Line: 03 – 2296 0888 CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322 |
|||
| Beacon Hospital Sdn Bhd | DR THO LYE MUN drtho.oncology@gmail.com | General line:
03 7620 7979 / 03 7787 2992 |
|||
| Non Small Cell Lung Cancer with ALK Inhibitor Resistant in Asian (Liquid Biopsy) | Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer (ARTOG-004) | Pantai Hospital Kuala Lumpur | DR THO LYE MUN drtho.oncology@gmail.com | General Line: 03 – 2296 0888 CRC: 03 – 2781 0888 Ext 4519/4520/4522 |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | SC: Yok Yong 03-79492120 (Research Room) |
|||
| Non Small Cell Lung Cancer in Asian (Observational) | A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study) (ATORG001) | Pantai Hospital Kuala Lumpur | DR THO LYE MUN drtho.oncology@gmail.com | General Line: 03 – 2296 0888
CRC: 03 – 2781 0888 |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | Dr Ho Gwo Fuang fuang@ummc.edu.my | SC: Wei Ying 03-79492120 (Research Room) |
|||
| Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) clinicalresearch@beaconhospital.com.my (Email) |
|||
| Malaysia, Non Small Cell Lung Cancer, Advnced or Metastatic | A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine (ML41262) | Beacon Hospital Sdn Bhd | DR THO LYE MUN drtho.oncology@gmail.com | General line: 03 7620 7979 / 03 7787 2992CRC: 03 -7787 2854 (Tel) clinicalresearch@beaconhospital.com.my (Email) |
|
| Non-Small Cell Lung Cancer, Locally Advanced or Metastatic | Genomic Profiling Study In Subjects With Locally Advanced/Metastatic Non-Small Cell Lung Cancer (ROCHE) | Kuala Lumpur Hospital (HKL) | Dr Ros Suzanna Ahmad Bustamam rossuzanna@gmail.com | General line: 03 – 2615 5555
CRC: 03 – 2615 5555 |
|
| Malaysia, Non Small Cell Lung Cancer, Advnced or Metastatic | A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine (ML41262) | Beacon Hospital Sdn Bhd | DR THO LYE MUN drtho.oncology@gmail.com | General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) clinicalresearch@beaconhospital.com.my (Email) |
|
| Progressed 1-2 ALK inhibitor with at least one second generatiion of ALK inhibitor | Plasma Molecular Profiling in ALK Inhibitor Resistant Non-Small Cell Lung Cancer | University of Malaya Medical Centre (UMMC) | CLICK HERE | ||
| Non-Small Cell Lung Cancer, Locally Advanced or Metastatic | Genomic Profiling Study In Subjects With Locally Advanced/Metastatic Non-Small Cell Lung Cancer (ROCHE) | Kuala Lumpur Hospital (HKL) | Dr Ros Suzanna Ahmad Bustamam rossuzanna@gmail.com | General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) crc.hkl@moh.gov.my (email) Crc Hkl / Clinical Research Centre HKL (Facebook) |
|
| Malaysia, Non Small Cell Lung Cancer, Advnced or Metastatic | A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine (ML41262) | Beacon Hospital Sdn Bhd | DR THO LYE MUN drtho.oncology@gmail.com | General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) clinicalresearch@beaconhospital.com.my (Email) |
|
| Asia Pacific, Non Small Cell Lung Cancer, Advnced or Metastatic | A Study of Non-Small Cell Lung Cancer Genomic Screening to Encourage Precision Medicine in Asia Pacific (LC-SCRUM-AP) | Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN drmuthuk@gmail.com | General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) crc.hkl@moh.gov.my (email) Crc Hkl / Clinical Research Centre HKL (Facebook) |
Cervical Cancer Ovarian Clear Cell Carcinoma N
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Metastatic and/or Recurrent Disease | Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing (A-TRAIN) | University of Malaya Medical Centre (UMMC) | DR WAN ZAMANIAH wzamaniah@ummc.edu.my | SC: Cryst Sari: 03-79492120 (Research Room) |
CLICK HERE |
| Kuala Lumpur Hospital (HKL) | |||||
| Sarawak General Hospital | DR VOON PEI JYE voonpj@yahoo.com | General line: 082 – 276666 CRC: 082-276820 (Tel) 082-276823 (Fax) Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
|||
| National Cancer Institute (IKN) | DR WONG YOKE FUI florencefui@yahoo.com | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) 03- 8892 5622 (Fax) |
Nasopharyngeal Carcinoma
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Nasopharyngeal Carcinoma | Asian multicenter prospective study of circulating tumor DNA sequencing (A-TRAIN Nasopharyngeal Carcinoma Project) | University of Malaya Medical Centre (UMMC) | DR VOON PEI JYE voonpj@yahoo.com | General line: 082 – 276666 CRC: 082-276820 (Tel) 082-276823 (Fax) Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
Rare Cancers
| TYPE | TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Promoting genomic medicine throughout Asia (MASTER KEY ASIA) | University of Malaya Medical Centre (UMMC) | DR ROZITA ABDUL MALIK rozita@ummc.edu.my |
SC: Yok Yong 03-79492120 (Research Room) |
CLICK HERE | |
| Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN drmuthuk@gmail.com |
General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) crc.hkl@moh.gov.my (email) Crc Hkl / Clinical Research Centre HKL (Facebook) |
|||
| National Cancer Institute (IKN) | General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) 03- 8892 5622 (Fax) |
||||
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN hwoeifen@yahoo.com | General line: 04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 Dr. Yoon Chee Kin, Ketua Jabatan dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar, Admin Manager zarinacu@gmail.com (Email) |
|||
| Sarawak General Hospital | General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook) |
||||
| Sultan Ismail Hospital, Johor Bahru | Dr Rangasamy Ramachandran | General line: 07 – 356 5000 CRC: 07 – 356 5000 ext: 2408 Dr Munirah Admin Manager drmunirah@hsi.gov.my (Email) |
The information above was last updated on 03 February 2023.
Source: http://clinicalresearch.my/
Links are from CLINICALTRIAL.GOV
